GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONCW) » Definitions » Cash-to-Debt

American Oncology Network (American Oncology Network) Cash-to-Debt : 0.82 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. American Oncology Network's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.82.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, American Oncology Network couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for American Oncology Network's Cash-to-Debt or its related term are showing as below:

AONCW' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29   Med: 0.5   Max: 0.82
Current: 0.82

During the past 4 years, American Oncology Network's highest Cash to Debt Ratio was 0.82. The lowest was 0.29. And the median was 0.50.

AONCW's Cash-to-Debt is ranked better than
53.36% of 669 companies
in the Healthcare Providers & Services industry
Industry Median: 0.69 vs AONCW: 0.82

American Oncology Network Cash-to-Debt Historical Data

The historical data trend for American Oncology Network's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

American Oncology Network Cash-to-Debt Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
N/A 0.43 0.29 0.50

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial 0.29 N/A 0.60 0.50 0.82

Competitive Comparison of American Oncology Network's Cash-to-Debt

For the Medical Care Facilities subindustry, American Oncology Network's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

American Oncology Network's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, American Oncology Network's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where American Oncology Network's Cash-to-Debt falls into.


American Oncology Network Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

American Oncology Network's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=63.928 / (7.881 + 120.444)
=0.50

American Oncology Network's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=105.049 / (7.92 + 120.642)
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

American Oncology Network  (OTCPK:AONCW) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

American Oncology Network Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of American Oncology Network's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

American Oncology Network (American Oncology Network) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONCW) » Definitions » Cash-to-Debt
Comparable Companies
PIII TOI BTMD AVAH CYH JYNT PNTG SNDA AIRS CCM HCA SAU:4013 SZSE:300015 HKSE:06618 XTER:FRE BKK:BDMS XKLS:5225 BSP:RDOR3 XTER:FME UHS
Traded in Other Exchanges
AONC:USA
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
Website
https://www.aoncology.com
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.